Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | IL22 |
| Gene Name: | IL22 |
| Protein Full Name: | Interleukin-22 |
| Alias: | Cytokine Zcyto18;IL-10-related T-cell-derived-inducible factor |
| Mass (Da): | 20011 |
| Number AA: | 179 |
| UniProt ID: | Q9GZX6 |
| Locus ID: | 50616 |
| COSMIC ID: | IL22 |
| Gene location on chromosome: | 12q15 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 19626 |
| Percent of cancer specimens with mutations: | 0.23 |
| Normal role description: | IL22 is a cytokine secreted by epithelial cells, natural killer cells and Th17 T-cells. IL22 binds the IL22 receptor to activate JAK/STAT and MAPK signalling pathways. IL22 is involved in mediating inflammation and wound healing. In cancer development, IL22 expression appears to aid in propagation and survival of cancer cells after transformation. Increased levels of serum IL22 is observed in lung cancer patients. Decreasing IL22 production prevented further growth of tumours. IL22 is also required for ALK-ALCL/NPM-ALK fusion mediated lymphomas to increase cell growth and proliferation via STAT3 activation. |